Multi-omic subtyping and molecular determinants of neoadjuvant therapeutic regimen for locally advanced HER2-positive and triple-negative breast cancer: Implications of novel therapy.
It's driving me nuts. Is the double bond constantly changing between all possibilities fast enough that it shortens the bond length for all, or are all the double bonds existing in all possible states ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results